trial

Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome

NCTId NCT04518319
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Suspended
Enrollment 120 (estimated)
Sponsored by Shanghai Mental Health Center
Primary completion 2024-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Suspended
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2020-10-01
Primary completion
2024-11
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Omega-3 polyunsaturated fatty acidsXbox aerobic exercisetranscranial direct current stimulation,tDCSOlanzapine

Sponsors

Shanghai Mental Health CenterLead Sponsor

Investigators

1
Yan ChenPrincipal Investigator

Sites

1 total
Shanghai, China

Linked catalysts

1
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Sy — primary completion2024-11

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE2
Primary Completion Date
2024-11
Status
SUSPENDED
relationships
The graph out of here
drug
Omega-3 polyunsaturated fatty acids
drug
Xbox aerobic exercise
drug
transcranial direct current stimulation,tDCS
drug
Olanzapine
drug
lead_sponsor
Shanghai Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Yan Chen
person